Iksuda Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10593
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprietary linker and stable glycan technologies permalink and premacarb to deliver solutions for development and manufacture efficacious and safe biologics to improve half-life and optimize bio-availability. The company partners with various biotech companies for its technology development activities. Iksuda is headquartered in Newcastle upon Tyne, the UK.

Iksuda Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Glythera Raises US$2 Million In Venture Financing 10
Partnerships 11
Avacta Enters into Agreement with Glythera 11
Licensing Agreements 12
Avacta Enters into Licensing Agreement with Glythera 12
Glythera Enters into Licensing Agreement with Cancer Research UK 13
Glythera Enters into Licensing Agreement with IONTAS 14
Iksuda Therapeutics Ltd – Key Competitors 15
Iksuda Therapeutics Ltd – Key Employees 16
Iksuda Therapeutics Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Apr 30, 2018: Glythera Names Professor Kerry Chester to Scientific Advisory Board 18
Jan 17, 2018: Glythera Appoints Chief Scientific Officer and Strengthens SAB 19
Jul 31, 2017: Glythera Appoints Dr Mike Owen as Non-executive Director 20
Jul 31, 2017: Glythera appoints new non-executive director 21
Government and Public Interest 22
Jun 06, 2017: Glythera Launches UK government funded project to develop safer and more efficacious ADCs for the treatment of difficult-to-treat tumours 22
Product News 23
Feb 21, 2017: Glythera: Demonstrates improved activity and safety of PermaLink-based ADCs 23
Other Significant Developments 24
Sep 10, 2018: Glythera announces corporate name change and rebranding to Iksuda Therapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Glythera Raises US$2 Million In Venture Financing 10
Avacta Enters into Agreement with Glythera 11
Avacta Enters into Licensing Agreement with Glythera 12
Glythera Enters into Licensing Agreement with Cancer Research UK 13
Glythera Enters into Licensing Agreement with IONTAS 14
Iksuda Therapeutics Ltd, Key Competitors 15
Iksuda Therapeutics Ltd, Key Employees 16

List of Figures
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Iksuda Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mobile Telesystems
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • EnviTec Biogas AG (ETG):企業の財務・戦略的SWOT分析
    EnviTec Biogas AG (ETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Vexim SA – Product Pipeline Analysis, 2018 Uate
    Summary Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controll …
  • YGM Trading Ltd.:企業の戦略・SWOT・財務情報
    YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • American Shared Hospital Services (AMS):企業の財務・戦略的SWOT分析
    Summary American Shared Hospital Services (ASHS) is a distributor of medical equipment to hospitals and medical centers. The company also offers financial and healthcare tech solutions. Its financing solutions comprise feasibility studies and reimbursement analysis, facilities planning and design, s …
  • Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacil …
  • C&A:企業の戦略・SWOT・財務情報
    C&A - Strategy, SWOT and Corporate Finance Report Summary C&A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • Hangzhou Hikvision Digital Technology Co Ltd (002415):企業の財務・戦略的SWOT分析
    Hangzhou Hikvision Digital Technology Co Ltd (002415) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • PT Bank CIMB Niaga Tbk (BNGA):企業の財務・戦略的SWOT分析
    PT Bank CIMB Niaga Tbk (BNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • WntResearch AB (WNT):製薬・医療:M&Aディール及び事業提携情報
    Summary WntResearch AB (WntResearch) is a biotechnology company that develops novel anti-metastatic therapies for the treatment of cancer. The company's development stage products include Foxy-5 and Box-5. Its lead project, Foxy-5, a peptide which is in Phase I clinical development for reconstitutin …
  • Cogeco Peer 1 (UK) Ltd:企業の戦略・SWOT・財務情報
    Cogeco Peer 1 (UK) Ltd - Strategy, SWOT and Corporate Finance Report Summary Cogeco Peer 1 (UK) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Vietnam Electricity Construction Joint – Stock Corp (VNE):電力:M&Aディール及び事業提携情報
    Summary Vietnam Electricity Construction Joint - Stock Corp (VNECO) is a diversified company. The company operates through its business divisions such as electricity construction, industrial production, delivery of equipment, investment power, and consulting services. Its electricity construction di …
  • Seattle Genetics Inc (SGEN):企業の財務・戦略的SWOT分析
    Seattle Genetics Inc (SGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Cardiac Dimensions Inc-医療機器分野:企業M&A・提携分析
    Summary Cardiac Dimensions Inc (Cardiac Dimensions) is a medical equipment provider that develops intervention tools used for treating heart failure and other related condition of mitral valve regurgitation. The company’s system uses a catheter based approach in order to reshape the mitral valve and …
  • Marathon Oil Corporation:企業の戦略・SWOT・財務情報
    Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Shopper’s Stop Ltd.:企業の戦略・SWOT・財務情報
    Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Fiat Chrysler Automobiles NV:企業のM&A・事業提携・投資動向
    Fiat Chrysler Automobiles NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fiat Chrysler Automobiles NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Harvard Bioscience Inc (HBIO):企業の財務・戦略的SWOT分析
    Harvard Bioscience Inc (HBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Encompass Health Corp (EHC):企業の財務・戦略的SWOT分析
    Encompass Health Corp (EHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Lietuvos energijos gamyba, AB (LNR1L)-エネルギー分野:企業M&A・提携分析
    Summary Lietuvos energijos gamyba, AB (Lietuvos), a subsidiary of Lietuvos Energija UAB, is a state-controlled electric utility that generates, imports and exports, and supplies electricity and thermal energy. It generates electricity from hydro, thermal and renewable energy sources. The company tra …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆